The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 13, 2011
Filed:
Jan. 24, 2005
Paul A. Bunn, Jr., Evergreen, CO (US);
Christopher D. Coldren, Denver, CO (US);
Wilbur A. Franklin, Denver, CO (US);
Mark W. Geraci, Aurora, CO (US);
Barbara A. Helfrich, Lakewood, CO (US);
Fred R. Hirsch, Denver, CO (US);
Razvan Lapadat, Denver, CO (US);
Michio Sugita, Centennial, CO (US);
Samir E. Witta, Greenwood Village, CO (US);
Paul A. Bunn, Jr., Evergreen, CO (US);
Christopher D. Coldren, Denver, CO (US);
Wilbur A. Franklin, Denver, CO (US);
Mark W. Geraci, Aurora, CO (US);
Barbara A. Helfrich, Lakewood, CO (US);
Fred R. Hirsch, Denver, CO (US);
Razvan Lapadat, Denver, CO (US);
Michio Sugita, Centennial, CO (US);
Samir E. Witta, Greenwood Village, CO (US);
The Regents of the University of Colorado, A Body Corporate, Denver, CO (US);
Abstract
Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to gefitinib and other EGFR inhibitors, and products and processes related thereto. Specifically, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for the detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.